AstraZeneca Pharma India Appoints Praveen K Mittal as Director - Corporate Affairs
AstraZeneca Pharma India Ltd has announced the appointment of Mr. Praveen K Mittal as Director - Corporate Affairs, effective July 6, 2026. The appointment is for a full-time position, according to company records.Mr. Mittal brings extensive experience in corporate affairs, government relations, and public policy to the role. He possesses nearly 30 years of experience across sectors including healthcare, medical technology, industry advocacy, and trade promotion.
Before joining AstraZeneca, Mr. Mittal served as the Executive Director of the Export Promotion Council for Medical Devices (EPCMD). In this capacity, he focused on driving policy advocacy, stakeholder engagement, international market development, and growing the industry ecosystem.
His professional history also includes over 18 years spent with FICCI, most recently serving as Assistant Secretary General and Head of the Healthcare Division. During his tenure at FICCI, Mr. Mittal worked closely with central and state government authorities, regulators, and policymakers, significantly contributing to the creation of healthcare and medical technology policy frameworks in India.
Mr. Mittal's specialized expertise encompasses public policy, industry advocacy, and stakeholder management, bolstered by extensive international exposure across North America, Europe, and Asia.
ASTRAZEN Stock Price Movement
As of 2:04 PM, shares of AstraZeneca Pharma India Limited are edging higher to ₹8442 today, with the stock gaining 0.22%. The equity is seeing active interest in live trading, trading volume currently standing at 1,661 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.